Nothing Special   »   [go: up one dir, main page]

DE60331297D1 - Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff - Google Patents

Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff

Info

Publication number
DE60331297D1
DE60331297D1 DE60331297T DE60331297T DE60331297D1 DE 60331297 D1 DE60331297 D1 DE 60331297D1 DE 60331297 T DE60331297 T DE 60331297T DE 60331297 T DE60331297 T DE 60331297T DE 60331297 D1 DE60331297 D1 DE 60331297D1
Authority
DE
Germany
Prior art keywords
oligonucleotide
nucleic acid
acid sequence
hydroxyal
reinforcing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60331297T
Other languages
English (en)
Inventor
Eric B Kmiec
Hetal Parekh-Olmedo
Erin E Brachman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Delaware
Original Assignee
University of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Delaware filed Critical University of Delaware
Application granted granted Critical
Publication of DE60331297D1 publication Critical patent/DE60331297D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60331297T 2002-03-07 2003-03-07 Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff Expired - Fee Related DE60331297D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36305302P 2002-03-07 2002-03-07
US36334102P 2002-03-07 2002-03-07
US36305402P 2002-03-07 2002-03-07
US41698302P 2002-10-07 2002-10-07
PCT/US2003/007217 WO2003075856A2 (en) 2002-03-07 2003-03-07 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea

Publications (1)

Publication Number Publication Date
DE60331297D1 true DE60331297D1 (de) 2010-04-01

Family

ID=27808811

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331297T Expired - Fee Related DE60331297D1 (de) 2002-03-07 2003-03-07 Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff

Country Status (9)

Country Link
US (1) US7566535B2 (de)
EP (1) EP1490013B1 (de)
JP (1) JP2005518817A (de)
AT (1) ATE458047T1 (de)
AU (1) AU2003220119A1 (de)
CA (1) CA2478479A1 (de)
DE (1) DE60331297D1 (de)
IL (1) IL163875A0 (de)
WO (1) WO2003075856A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
EP2342337B1 (de) 2008-09-11 2015-05-27 Keygene N.V. Verfahren zur entwicklung diagnostischer marker
US8993328B2 (en) * 2008-09-22 2015-03-31 Rutgers, The State University Of New Jersey Media conditioning for improving gene delivery efficiency to differentiating embryonic stem cells
EP3140269B1 (de) 2014-05-09 2023-11-29 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
WO2016094845A2 (en) 2014-12-12 2016-06-16 Woolf Tod M Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US20180003711A1 (en) * 2014-12-22 2018-01-04 Universität Zürich Directed evolution of membrane proteins in eukaryotic cells with a cell wall
AU2017221405A1 (en) 2016-02-16 2018-09-20 Carnegie Mellon University Compositions for enhancing targeted gene editing and methods of use thereof
CA3048501A1 (en) * 2017-01-10 2018-07-19 Christiana Care Health Services, Inc. Methods for in vitro site-directed mutagenesis using gene editing technologies
US20210024882A1 (en) * 2019-07-08 2021-01-28 Life Technologies Corporation Compositions and methods for enhancing cell culture
WO2021207673A1 (en) * 2020-04-09 2021-10-14 The Regents of the University of Colorodo, a body corporate Compositions, methods and uses for production of hematopoietic stem cells (hscs)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US217377A (en) * 1879-07-08 hislop
US51270A (en) * 1865-11-28 Improvement in children s bedclothes-retainers
US143052A (en) * 1873-09-23 Improvement in flexible vertically-extensible attachments for boats
US119570A (en) * 1871-10-03 Improvement in coopers crozes and howels
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5955363A (en) * 1990-01-03 1999-09-21 Promega Corporation Vector for in vitro mutagenesis and use thereof
US5432272A (en) * 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
PT733059E (pt) * 1993-12-09 2001-03-30 Univ Jefferson Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5780296A (en) * 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えdnaウイルスおよびその製造方法
US5776744A (en) * 1995-06-07 1998-07-07 Yale University Methods and compositions for effecting homologous recombination
US5912340A (en) * 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5888983A (en) * 1996-05-01 1999-03-30 Thomas Jefferson University Method and oligonucleobase compounds for curing diseases caused by mutations
US5760012A (en) * 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
US5731181A (en) * 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
WO1997047307A1 (en) 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
ES2192672T3 (es) * 1996-11-18 2003-10-16 Takeshi Imanishi Nuevos analogos de nucleotidos.
WO1998026060A2 (en) * 1996-12-12 1998-06-18 Julianna Lisziewicz Materials and methods for gene transfer
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6821759B1 (en) * 1997-06-23 2004-11-23 The Rockefeller University Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
US6004804A (en) * 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
CA2346943A1 (en) 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
CA2346152A1 (en) 1998-10-16 2000-04-27 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
DE19983694T1 (de) 1998-10-28 2002-05-29 Univ Washington Seattle Zielgerichtete Genmodifikation durch parvovirale Vektoren
JP2002538348A (ja) 1999-02-24 2002-11-12 ナムローゼ・フェンノートシャップ・ケマ 液体燃料を燃焼させるための燃焼ユニット及び該燃焼ユニットを含む動力生成システム
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
KR20010112301A (ko) 1999-03-02 2001-12-20 질레스피 카롤 리포좀내에 생활성 복합체의 포집
EP1159415B1 (de) 1999-03-04 2009-12-23 Revivicor, Inc. Genetische veränderung von somatischen zellen und deren verwendungen
DE60044241D1 (de) 1999-03-18 2010-06-02 Exiqon As Xylo-lna analoge
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 L-리보-lna 유사체
AU5886000A (en) * 1999-06-25 2001-01-31 Northwestern University Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
US6271360B1 (en) * 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2383885A1 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
PL200861B1 (pl) 1999-09-08 2009-02-27 Sloan Kettering Inst Cancer Pochodna kwasu suberynowego, jej zastosowanie i kompozycja farmaceutyczna
AR025996A1 (es) 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
EP1230394A4 (de) 1999-11-10 2002-12-18 Uab Research Foundation Vektortransduktion hematopoietischer stammzellen mittels lentivirus
AU783504C (en) 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
EP1252196B1 (de) 2000-01-05 2005-11-02 Novartis AG Hydrogele
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
IL151948A0 (en) 2000-03-27 2003-04-10 Univ Delaware Oligonucleotides for targeted alteration of a genetic sequence and methods utilizing the same
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1170008A1 (de) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
EP1302476B1 (de) 2000-07-17 2009-03-11 Astellas Pharma Inc. Reduziertes fk228 und seine verwendung
IL154099A0 (en) 2000-07-27 2003-07-31 Univ Delaware A method and kit for enhancing oligonucleotide-mediated gene alteration
EP1311661B1 (de) * 2000-08-14 2012-10-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erhöhte homologe rekombination vermittelt durch lambda rekombinationsproteine
WO2002026967A2 (en) 2000-09-25 2002-04-04 Thomas Jefferson University Targeted gene correction by single-stranded oligodeoxynucleotides
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors

Also Published As

Publication number Publication date
IL163875A0 (en) 2005-12-18
CA2478479A1 (en) 2003-09-18
EP1490013B1 (de) 2010-02-17
WO2003075856A2 (en) 2003-09-18
US7566535B2 (en) 2009-07-28
US20030207451A1 (en) 2003-11-06
ATE458047T1 (de) 2010-03-15
WO2003075856A3 (en) 2004-06-24
EP1490013A4 (de) 2005-12-28
JP2005518817A (ja) 2005-06-30
EP1490013A2 (de) 2004-12-29
AU2003220119A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
DE60331297D1 (de) Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
ATE336583T1 (de) Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung
DE69701671D1 (de) Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekulen
DE59712890D1 (de) Neues gen für eine aminosäure-deacetylase mit spezifität für n-acetyl-l-phosphinothricin, ihre isolierung und verwendung
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
DE69723074D1 (de) Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung
DK1809750T3 (da) Selektion af værtsceller, der udtrykker protein ved høje niveauer
DE602007009498D1 (de) Neue fluoreszenzproteine und verfahren zur verwendung davon
ATE319814T1 (de) Luciferase, fluoreszenzproteine, für luciferase und fluoreszenzproteine kodierend nukleinsaüre und ihre verwendung in der diagnose, hoch- durchsatz screeningsverfahren
ATE471387T1 (de) Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
DE60238449D1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
DE60333486D1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
ATE408029T1 (de) Verfahren zur herstellung und identifizierung löslicher proteindomänen
ATE391727T1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
DE60330564D1 (de) Verfahren und konstrukte zur expression von clostripain mit hoher ausbeute
ATE479745T1 (de) Nukleotidsequenzen codierend für deregulierte phosphoglycerat-dehydrogenasen coryneformer bakterien sowie verfahren zur herstellung von l- serin
ATE379967T1 (de) Nukleinsäuren kodierend miteinander verbundene chromo/fluoreszenzdomänen und verfahren zu ihrer verwendung
ATE288487T1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
DE60326640D1 (de) Rekombinante biotincarboxylasedomänen zur identifizierung von acetyl-coa-carboxylase-inhibitoren
ATE392480T1 (de) Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen
ATE318317T1 (de) Verfahren zur erhöhung der expression von einem interessierenden protein durch rekombinante wirtzellen
DE50312072D1 (de) Verfahren zur identifizierung von substanzen
DE602004021922D1 (de) Induktion der blütenbildung

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee